tldrdailynews.com logo

Novartis in Talks to Acquire MorphoSys, Karyopharm Surges in Sympathy

1 min read
Source: Seeking Alpha
Novartis in Talks to Acquire MorphoSys, Karyopharm Surges in Sympathy
Photo: Seeking Alpha
TL;DR

MorphoSys AG's ADRs surged 58% following reports of advanced takeover talks with Novartis, potentially edging out a rival bid from Incyte. The cancer drugmaker has attracted interest from three large pharmaceutical companies, with two based in Europe and one in the U.S. Karyopharm Therapeutics also saw a 37% surge in sympathy with the news, as analysts anticipate potential readthrough and continued upside for the company amidst the takeover speculation.

Topics:businessfinance#finance#karyopharm-therapeutics#morphosys#novartis#pharmaceutical-companies#takeover-talks
Share this article
  1. MorphoSys jumps amid report Novartis in takeover talks; Karyopharm surges in sympathy  Seeking Alpha
  2. Exclusive: Novartis in the lead to acquire cancer drug developer MorphoSys-sources  Reuters
  3. Novartis to Buy Morphosys for €2.7 Billion to Gain Cancer Drugs  Bloomberg
  4. Why Is MorphoSys (MOR) Stock Up 50% Today?  InvestorPlace
  5. Novartis eyes MorphoSys buyout: Reuters  FiercePharma

Want the full story? Read the original reporting

Read on Seeking Alpha